首页 > 最新文献

Antiviral Therapy最新文献

英文 中文
Discovery and development of oseltamivir at Gilead Sciences 吉利德科学公司奥司他韦的发现和开发
IF 1.2 4区 医学 Q4 INFECTIOUS DISEASES Pub Date : 2022-04-01 DOI: 10.1177/13596535211067598
U. Schmitz, S. Swaminathan
John Martin’s untimely death in March 2021 was a huge loss for us personally, Gilead Sciences, the company he built over 30 years and the scientific community concerned with antiviral therapies. We wish to honor John’s legacy by retelling the discovery and history of Tamiflu and his contributions to it. Without his vision, persistence, and keen eye for opportunities, Tamiflu would not exist and Gilead’s path would not have been the same. His strategic thinking around the first oral flu drug is still quite relevant today, when we are still in the SARS-CoV-2 pandemic. John explained it simply in an interview with the Science History Institute in May 2020: “…most of my colleagues, we travel with Tamiflu when we go internationally, because it works for treatment and prevention, and hopefully, there will be a solution like that, eventually, for the Covid virus in addition to vaccines. Most people will get a flu vaccine every year, but there is still disease, we need a pill for treatment and prevention.”
约翰·马丁于2021年3月英年早逝,这对我们个人、吉利德科学公司、他30多年来建立的公司以及关注抗病毒疗法的科学界来说都是一个巨大的损失。我们希望通过复述达菲的发现和历史以及他对达菲的贡献来纪念约翰的遗产。如果没有他的远见、毅力和对机会的敏锐眼光,达菲就不会存在,吉利德的道路也不会一样。在我们仍处于严重急性呼吸系统综合征冠状病毒2型大流行的今天,他对第一种口服流感药物的战略思考仍然非常重要。约翰在2020年5月接受科学历史研究所采访时简单地解释了这一点:“……我的大多数同事,当我们去国际旅行时,我们都会带着达菲旅行,因为它对治疗和预防有效,希望最终除了疫苗之外,新冠肺炎病毒也会有这样的解决方案。大多数人每年都会接种流感疫苗,但仍有疾病,我们需要一片治疗和预防药物。”
{"title":"Discovery and development of oseltamivir at Gilead Sciences","authors":"U. Schmitz, S. Swaminathan","doi":"10.1177/13596535211067598","DOIUrl":"https://doi.org/10.1177/13596535211067598","url":null,"abstract":"John Martin’s untimely death in March 2021 was a huge loss for us personally, Gilead Sciences, the company he built over 30 years and the scientific community concerned with antiviral therapies. We wish to honor John’s legacy by retelling the discovery and history of Tamiflu and his contributions to it. Without his vision, persistence, and keen eye for opportunities, Tamiflu would not exist and Gilead’s path would not have been the same. His strategic thinking around the first oral flu drug is still quite relevant today, when we are still in the SARS-CoV-2 pandemic. John explained it simply in an interview with the Science History Institute in May 2020: “…most of my colleagues, we travel with Tamiflu when we go internationally, because it works for treatment and prevention, and hopefully, there will be a solution like that, eventually, for the Covid virus in addition to vaccines. Most people will get a flu vaccine every year, but there is still disease, we need a pill for treatment and prevention.”","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42691471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study 替诺福韦阿拉那胺治疗48周后慢性乙型肝炎患者血脂的变化:一项前瞻性现实世界临床研究
IF 1.2 4区 医学 Q4 INFECTIOUS DISEASES Pub Date : 2022-04-01 DOI: 10.1177/13596535221082399
Yeqiong Zhang, Zhipeng Li, Q. Luo, Wenxiong Xu, Lu Wang, Shu Zhu, L. Peng, Chang Xie
Background Tenofovir alafenamide (TAF) is a new anti-hepatitis B virus nucleotide analogue that can cause dyslipidaemia in AIDS patients, but the effect of TAF on blood lipids in patients with chronic hepatitis B (CHB) is unknown. This study aimed to evaluate the effect of TAF on blood lipid levels in patients with CHB. Methods One hundred and twenty-one CHB patients were recruited as TAF group, including 69 treatment-naïve patients and 52 patients with nucleoside/nucleotide analogue experience before TAF treatment. All patients were followed up regularly for 48 weeks. Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels and the incidence of dyslipidaemia before and after TAF treatment were compared. Results After 48 weeks of TAF treatment, the levels of TC, TGs and LDL-C in TAF group were significantly higher than those in control group. In TAF group, the TC and TG levels were significantly higher than that at baseline. Baseline TC and TGs levels had a significant effect on the incidence of abnormal TC and TG levels after 48 weeks treatment. The LDL-C decreased slightly but not significantly. The proportion of patients with TC abnormalities increased from 20.7% at baseline to 26.3% at week 48, LDL-C abnormalities decreased from 50.4% to 42.5% and TG abnormalities increased from 14.2% to 22.5%. There were no significant differences compared with control group, as well as compared with baseline. Conclusions Tenofovir alafenamide treatment mainly affects the TC and TG level in patients with CHB but has little effect on LDL-C.
替诺福韦阿拉芬胺(TAF)是一种新的抗乙型肝炎病毒核苷酸类似物,可引起艾滋病患者血脂异常,但TAF对慢性乙型肝炎(CHB)患者血脂的影响尚不清楚。本研究旨在评估TAF对慢性乙型肝炎患者血脂水平的影响。方法121例CHB患者作为TAF组,其中treatment-naïve患者69例,TAF治疗前有核苷/核苷酸类似物治疗经验的患者52例。所有患者定期随访48周。比较TAF治疗前后总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)水平及血脂异常发生率。结果TAF治疗48周后,TAF组TC、tg、LDL-C水平均显著高于对照组。TAF组TC、TG水平明显高于基线。治疗48周后,基线TC和TG水平对TC和TG异常发生率有显著影响。LDL-C略有下降,但不明显。TC异常的患者比例从基线时的20.7%上升到第48周时的26.3%,LDL-C异常从50.4%下降到42.5%,TG异常从14.2%上升到22.5%。与对照组及基线比较均无显著差异。结论替诺福韦alafenamide治疗主要影响CHB患者TC和TG水平,对LDL-C影响不大。
{"title":"Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study","authors":"Yeqiong Zhang, Zhipeng Li, Q. Luo, Wenxiong Xu, Lu Wang, Shu Zhu, L. Peng, Chang Xie","doi":"10.1177/13596535221082399","DOIUrl":"https://doi.org/10.1177/13596535221082399","url":null,"abstract":"Background Tenofovir alafenamide (TAF) is a new anti-hepatitis B virus nucleotide analogue that can cause dyslipidaemia in AIDS patients, but the effect of TAF on blood lipids in patients with chronic hepatitis B (CHB) is unknown. This study aimed to evaluate the effect of TAF on blood lipid levels in patients with CHB. Methods One hundred and twenty-one CHB patients were recruited as TAF group, including 69 treatment-naïve patients and 52 patients with nucleoside/nucleotide analogue experience before TAF treatment. All patients were followed up regularly for 48 weeks. Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels and the incidence of dyslipidaemia before and after TAF treatment were compared. Results After 48 weeks of TAF treatment, the levels of TC, TGs and LDL-C in TAF group were significantly higher than those in control group. In TAF group, the TC and TG levels were significantly higher than that at baseline. Baseline TC and TGs levels had a significant effect on the incidence of abnormal TC and TG levels after 48 weeks treatment. The LDL-C decreased slightly but not significantly. The proportion of patients with TC abnormalities increased from 20.7% at baseline to 26.3% at week 48, LDL-C abnormalities decreased from 50.4% to 42.5% and TG abnormalities increased from 14.2% to 22.5%. There were no significant differences compared with control group, as well as compared with baseline. Conclusions Tenofovir alafenamide treatment mainly affects the TC and TG level in patients with CHB but has little effect on LDL-C.","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44319361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The curing regimens of HCV: A SWOT analysis 丙型肝炎病毒治疗方案的SWOT分析
IF 1.2 4区 医学 Q4 INFECTIOUS DISEASES Pub Date : 2022-04-01 DOI: 10.1177/13596535211072672
M. Cornberg, M. Manns
The development of direct-acting antivirals (DAA) has revolutionized the treatment of chronic hepatitis C, enabling cure of hepatitis C virus (HCV) infection in more than 95% of cases. There are essentially no contraindications, so almost any patient can now be successfully treated. The result is the prevention or amelioration of cirrhosis, hepatocellular carcinoma (HCC), and extrahepatic manifestations. Consequently, the 2020 Nobel Prize in Medicine and Physiology was awarded for the discovery of HCV. Due to the high efficacy of therapy, even global HCV elimination is conceivable even without a vaccine. Here, we would like to venture a SWOT analysis of current HCV therapies aimed at HCV elimination.
直接作用抗病毒药物(DAA)的开发彻底改变了慢性丙型肝炎的治疗,使95%以上的病例能够治愈丙型肝炎病毒(HCV)感染。基本上没有禁忌症,所以现在几乎任何患者都可以成功治疗。其结果是预防或改善肝硬化、肝细胞癌(HCC)和肝外表现。因此,2020年诺贝尔医学和生理学奖因丙型肝炎病毒的发现而获得。由于治疗的高效性,即使没有疫苗,也可以想象全球消除丙型肝炎病毒。在这里,我们想对目前旨在消除丙型肝炎病毒的丙型肝炎病毒疗法进行SWOT分析。
{"title":"The curing regimens of HCV: A SWOT analysis","authors":"M. Cornberg, M. Manns","doi":"10.1177/13596535211072672","DOIUrl":"https://doi.org/10.1177/13596535211072672","url":null,"abstract":"The development of direct-acting antivirals (DAA) has revolutionized the treatment of chronic hepatitis C, enabling cure of hepatitis C virus (HCV) infection in more than 95% of cases. There are essentially no contraindications, so almost any patient can now be successfully treated. The result is the prevention or amelioration of cirrhosis, hepatocellular carcinoma (HCC), and extrahepatic manifestations. Consequently, the 2020 Nobel Prize in Medicine and Physiology was awarded for the discovery of HCV. Due to the high efficacy of therapy, even global HCV elimination is conceivable even without a vaccine. Here, we would like to venture a SWOT analysis of current HCV therapies aimed at HCV elimination.","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43979178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The transformation of HIV therapy: One pill once a day HIV治疗的转变:每天一粒
IF 1.2 4区 医学 Q4 INFECTIOUS DISEASES Pub Date : 2022-04-01 DOI: 10.1177/13596535211062396
Madhuchanda Choudhary, J. Mellors
A co-formulated, one pill once a day antiretroviral regimen (single-tablet regimen), containing efavirenz, emtricitabine, and tenofovir disoproxyl fumarate (Atripla), revolutionized the antiretroviral therapy landscape. Single-tablet regimens provide not only dosing convenience but help optimize adherence and persistence with antiretroviral therapy to achieve durably suppressed viremia with both individual and societal benefits. Given the many excellent options available now, single-tablet regimens are the preferred choice for initiating antiretroviral therapy in almost all patients with rare exceptions for drug interactions and pregnancy, and for simplification of more complex antiretroviral therapy to a single-tablet regimen. In this special commemorative article, we celebrate this astounding advancement in antiretroviral therapy, championed by John C. Martin while CEO of Gilead Sciences, and its transformative impact on HIV care nationally and globally.
一种含有依非韦伦、恩曲他滨和富马酸替诺福韦二丙酯(Atripla)的联合配方、每天一片的抗逆转录病毒疗法(单片疗法)彻底改变了抗逆转录病毒治疗的格局。单片方案不仅给药方便,而且有助于优化抗逆转录病毒疗法的依从性和持久性,以实现持久抑制的病毒血症,并带来个人和社会效益。鉴于目前有许多优秀的选择,单片方案是几乎所有患者开始抗逆转录病毒治疗的首选方案,药物相互作用和妊娠的罕见例外,以及将更复杂的抗逆转录病毒疗法简化为单片方案的首选方案。在这篇特别的纪念文章中,我们庆祝由吉利德科学公司首席执行官约翰·C·马丁倡导的抗逆转录病毒疗法的这一惊人进步,以及它对全国和全球艾滋病毒护理的变革性影响。
{"title":"The transformation of HIV therapy: One pill once a day","authors":"Madhuchanda Choudhary, J. Mellors","doi":"10.1177/13596535211062396","DOIUrl":"https://doi.org/10.1177/13596535211062396","url":null,"abstract":"A co-formulated, one pill once a day antiretroviral regimen (single-tablet regimen), containing efavirenz, emtricitabine, and tenofovir disoproxyl fumarate (Atripla), revolutionized the antiretroviral therapy landscape. Single-tablet regimens provide not only dosing convenience but help optimize adherence and persistence with antiretroviral therapy to achieve durably suppressed viremia with both individual and societal benefits. Given the many excellent options available now, single-tablet regimens are the preferred choice for initiating antiretroviral therapy in almost all patients with rare exceptions for drug interactions and pregnancy, and for simplification of more complex antiretroviral therapy to a single-tablet regimen. In this special commemorative article, we celebrate this astounding advancement in antiretroviral therapy, championed by John C. Martin while CEO of Gilead Sciences, and its transformative impact on HIV care nationally and globally.","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44712129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Tenofovir alafenamide fumarate 富马酸替诺福韦
IF 1.2 4区 医学 Q4 INFECTIOUS DISEASES Pub Date : 2022-02-01 DOI: 10.1177/13596535211067600
William A Lee, A. Cheng
Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the cells that replicate HIV. Due to its selectivity for these tissues, lower total doses of TAF can be administered relative to tenofovir disoproxil fumarate (TDF) which results in improved bone and renal biomarkers. Tenofovir alafenamide fumarate has become the “backbone” of multiple combination products for the treatment of HIV, combined with emtricitabine for PreP and as a monotherapy for the treatment or HBV.
富马酸替诺福韦阿拉胺是替诺福韦的亲脂性前药,在淋巴组织中优先代谢,导致在复制HIV的细胞内产生高浓度的替诺福韦(TFV)及其活性二磷酸代谢物。由于其对这些组织的选择性,相对于富马酸替诺福韦二氧吡酯(TDF), TAF的总剂量可以降低,从而改善骨骼和肾脏生物标志物。富马酸替诺福韦阿拉那胺已成为治疗HIV的多种联合产品的“骨干”,与恩曲他滨联合用于PreP,并作为治疗HBV的单一疗法。
{"title":"Tenofovir alafenamide fumarate","authors":"William A Lee, A. Cheng","doi":"10.1177/13596535211067600","DOIUrl":"https://doi.org/10.1177/13596535211067600","url":null,"abstract":"Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the cells that replicate HIV. Due to its selectivity for these tissues, lower total doses of TAF can be administered relative to tenofovir disoproxil fumarate (TDF) which results in improved bone and renal biomarkers. Tenofovir alafenamide fumarate has become the “backbone” of multiple combination products for the treatment of HIV, combined with emtricitabine for PreP and as a monotherapy for the treatment or HBV.","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45072979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection 评论:先天性巨细胞病毒感染治疗方法的进展
IF 1.2 4区 医学 Q4 INFECTIOUS DISEASES Pub Date : 2022-02-01 DOI: 10.1177/13596535211060968
R. Whitley
In the mid 1980’s, I flew from Birmingham, Alabama to San Francisco, rented a car, and drove to Palo Alto so that I could meet with John Martin at Syntex. John, along with Julian Verheyden, synthesized ganciclovir, which had significant in vitro activity against cytomegalovirus (CMV) in vitro. This drug provided my colleagues and me an opportunity to evaluate it as a therapeutic agent for congenital CMV infection, knowing full well that it was mutagenic, teratogenic, and carcinogenic. John in his wisdom convinced the management of Syntex to provide ganciclovir for this disease, allowing me to study this drug in symptomatic congenitally infected children through the NIAID Collaborative Antiviral Study Group (CASG). Certainly, no other person or company would advocate for the use of such a medication in children, regardless of disease severity, because of its toxicity profile. Since these early days, ganciclovir, and subsequently its prodrug valganciclovir, have become the standard of care for the treatment of congenital cytomegalovirus infection. The following commentary defines the need and progress in the development of therapy
80年代中期,我从阿拉巴马州的伯明翰飞到旧金山,租了一辆车,然后开车到帕洛阿尔托,在Syntex公司与约翰·马丁会面。John和Julian Verheyden在体外合成了更昔洛韦(ganciclovir),该药物对巨细胞病毒(CMV)具有显著的体外抗活性。这种药物为我和我的同事提供了一个机会来评估它作为先天性巨细胞病毒感染的治疗药物,我们完全知道它是诱变的、致畸的和致癌的。约翰以他的智慧说服了Syntex的管理层为这种疾病提供更昔洛韦,使我能够通过NIAID协同抗病毒研究小组(CASG)研究这种药物在有症状的先天性感染儿童中的作用。当然,没有其他个人或公司会提倡在儿童中使用这种药物,无论疾病严重程度如何,因为它的毒性。从早期开始,更昔洛韦及其前药缬更昔洛韦就成为治疗先天性巨细胞病毒感染的标准药物。下面的评论定义了治疗发展的需要和进展
{"title":"Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection","authors":"R. Whitley","doi":"10.1177/13596535211060968","DOIUrl":"https://doi.org/10.1177/13596535211060968","url":null,"abstract":"In the mid 1980’s, I flew from Birmingham, Alabama to San Francisco, rented a car, and drove to Palo Alto so that I could meet with John Martin at Syntex. John, along with Julian Verheyden, synthesized ganciclovir, which had significant in vitro activity against cytomegalovirus (CMV) in vitro. This drug provided my colleagues and me an opportunity to evaluate it as a therapeutic agent for congenital CMV infection, knowing full well that it was mutagenic, teratogenic, and carcinogenic. John in his wisdom convinced the management of Syntex to provide ganciclovir for this disease, allowing me to study this drug in symptomatic congenitally infected children through the NIAID Collaborative Antiviral Study Group (CASG). Certainly, no other person or company would advocate for the use of such a medication in children, regardless of disease severity, because of its toxicity profile. Since these early days, ganciclovir, and subsequently its prodrug valganciclovir, have become the standard of care for the treatment of congenital cytomegalovirus infection. The following commentary defines the need and progress in the development of therapy","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44304098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Preemptive acyclovir to prevent herpes simplex virus bronchopneumonitis in mechanically ventilated patients with herpes simplex virus oropharyngeal reactivation: An ancillary study of the preemptive treatment for herpesviridae trial 单纯疱疹病毒口咽再激活机械通气患者预防性阿昔洛韦预防单纯疱疹病毒支气管肺炎:一项针对单纯疱疹病毒试验的预防性治疗的辅助研究
IF 1.2 4区 医学 Q4 INFECTIOUS DISEASES Pub Date : 2022-02-01 DOI: 10.1177/13596535211072673
Antoine Troger, S. Burrel, M. Pineton de Chambrun, M. Schmidt, N. Brechot, Olivier Bomme, G. Hékimian, A. Combes, D. Boutolleau, C. Luyt
Background To evaluate the impact of preemptive acyclovir treatment on herpes simplex virus (HSV) bronchopneumonitis in mechanically ventilated patients with HSV oropharyngeal reactivation. Methods Ancillary study of the Preemptive Treatment for Herpesviridae (PTH) clinical trial. Patients included in that trial from one centre (Pitié-Salpêtrière Hospital) and in whom at least one bronchoalveolar lavage (BAL) was performed for ventilator-associated pneumonia suspicion were included in the present study. Rate of HSV bronchopneumonitis, defined as clinical symptoms suggesting of pneumonia and presence of HSV in BAL fluid ≥105 copies of HSV/106 cells, were compared in patients who received either acyclovir or placebo. Results Eighty-three patients were included; 40 having received preemptive acyclovir and 43 having received a placebo, without differences between groups at admission or at randomization. The number of patients who developed HSV bronchopneumonitis was lower among acyclovir-treated patients than among placebo-treated patients (40% vs. 72%, respectively, p = .003). Results were similar when restricted to patients without HSV detected in the lower respiratory tract at randomization (31% vs. 61%, respectively, p = .03). Conclusions Preemptive acyclovir treatment in mechanically ventilated patients with HSV oropharyngeal reactivation reduces HSV bronchopneumonitis rate.
背景:在单纯疱疹病毒口咽再激活的机械通气患者中,评估先发制人的阿昔洛韦治疗对单纯疱疹病毒(HSV)支气管肺炎的影响。方法辅助研究疱疹病毒科(PTH)预防性治疗的临床试验。本研究纳入了来自一个中心(Pitié-Salpêtrière医院)的试验患者,这些患者至少接受了一次支气管肺泡灌洗(BAL)治疗,怀疑是呼吸机相关性肺炎。在接受阿昔洛韦或安慰剂治疗的患者中,比较HSV支气管肺炎的发生率,即表明肺炎的临床症状和BAL液中存在HSV≥105拷贝HSV/106细胞。结果83例患者入选;40人接受了先发制人的阿昔洛韦治疗,43人接受了安慰剂治疗,在入院或随机分组时各组之间没有差异。在阿昔洛韦治疗的患者中,发生HSV支气管肺炎的患者数量低于安慰剂治疗的患者(分别为40%和72%,p=0.003)。当随机分组时仅限于下呼吸道未检测到HSV的患者时,结果相似(分别为31%和61%,p=0.03)HSV口咽再激活的通气患者可降低HSV支气管肺炎的发生率。
{"title":"Preemptive acyclovir to prevent herpes simplex virus bronchopneumonitis in mechanically ventilated patients with herpes simplex virus oropharyngeal reactivation: An ancillary study of the preemptive treatment for herpesviridae trial","authors":"Antoine Troger, S. Burrel, M. Pineton de Chambrun, M. Schmidt, N. Brechot, Olivier Bomme, G. Hékimian, A. Combes, D. Boutolleau, C. Luyt","doi":"10.1177/13596535211072673","DOIUrl":"https://doi.org/10.1177/13596535211072673","url":null,"abstract":"Background To evaluate the impact of preemptive acyclovir treatment on herpes simplex virus (HSV) bronchopneumonitis in mechanically ventilated patients with HSV oropharyngeal reactivation. Methods Ancillary study of the Preemptive Treatment for Herpesviridae (PTH) clinical trial. Patients included in that trial from one centre (Pitié-Salpêtrière Hospital) and in whom at least one bronchoalveolar lavage (BAL) was performed for ventilator-associated pneumonia suspicion were included in the present study. Rate of HSV bronchopneumonitis, defined as clinical symptoms suggesting of pneumonia and presence of HSV in BAL fluid ≥105 copies of HSV/106 cells, were compared in patients who received either acyclovir or placebo. Results Eighty-three patients were included; 40 having received preemptive acyclovir and 43 having received a placebo, without differences between groups at admission or at randomization. The number of patients who developed HSV bronchopneumonitis was lower among acyclovir-treated patients than among placebo-treated patients (40% vs. 72%, respectively, p = .003). Results were similar when restricted to patients without HSV detected in the lower respiratory tract at randomization (31% vs. 61%, respectively, p = .03). Conclusions Preemptive acyclovir treatment in mechanically ventilated patients with HSV oropharyngeal reactivation reduces HSV bronchopneumonitis rate.","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46182379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polaris Observatory—supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis 北极星观察站——支持国家、地区和全球层面的知情决策,以消除病毒性肝炎
IF 1.2 4区 医学 Q4 INFECTIOUS DISEASES Pub Date : 2022-02-01 DOI: 10.1177/13596535221083179
H. Razavi
Background: Tools to eliminate Hepatitis B and C have been available and in 2016, the World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis. However, the adoption of hepatitis elimination programs has remained slow. Research design: The Center for Disease Analysis created a universal registry, the Polaris Observatory, to support informed decision-making at the national, regional, and global level for HCV and HBV elimination. The observatory covers 110 countries for HCV and 135 countries for HBV and provides decision analytics, disease burden modeling, economic impact assessments, and training to help countries with their national hepatitis elimination programs. Results: By providing reliable and up-to-date country specific data and analyses, demonstrating the impact of decisions, and providing costing estimates of national programs, our collaborating countries are making informed decisions. Our economic impact analyses also helped countries fund their elimination programs and negotiate prices. Polaris Observatory is an example of impactful private–public partnership where funding by the John C. Martin Foundation allowed support for informed decision-making by public agencies and national governments who would not/could not support such programs on their own. Conclusions: The catalytic funding allowed the Polaris Observatory to demonstrate the utility of such a program resulting in other donors to support this work. The Polaris Observatory is now supported through a portfolio of funders while our work and outputs remain independent to continue support for viral hepatitis elimination by year 2030.
背景:消除乙型和丙型肝炎的工具已经问世,2016年,世界卫生大会批准了《全球卫生部门应对病毒性肝炎战略》。然而,消除肝炎方案的实施仍然缓慢。研究设计:疾病分析中心创建了一个通用的登记处,即北极星天文台,以支持国家、地区和全球层面的HCV和HBV消除知情决策。该观察站覆盖了110个国家的丙型肝炎病毒和135个国家的乙型肝炎病毒,并提供决策分析、疾病负担建模、经济影响评估和培训,以帮助各国实施国家肝炎消除计划。结果:通过提供可靠和最新的针对具体国家的数据和分析,展示决策的影响,并提供国家项目的成本估算,我们的合作国家正在做出明智的决策。我们的经济影响分析还帮助各国为其淘汰计划提供资金并谈判价格。北极星天文台是一个有影响力的公私合作伙伴关系的例子,约翰·C·马丁基金会的资助使公共机构和国家政府能够支持知情决策,而这些机构和政府本身不会/不能支持此类项目。结论:催化资金使北极星天文台能够证明这样一个项目的实用性,从而吸引了其他捐助者来支持这项工作。北极星天文台现在由一系列资助者提供支持,而我们的工作和产出仍然独立,以继续支持到2030年消除病毒性肝炎。
{"title":"Polaris Observatory—supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis","authors":"H. Razavi","doi":"10.1177/13596535221083179","DOIUrl":"https://doi.org/10.1177/13596535221083179","url":null,"abstract":"Background: Tools to eliminate Hepatitis B and C have been available and in 2016, the World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis. However, the adoption of hepatitis elimination programs has remained slow. Research design: The Center for Disease Analysis created a universal registry, the Polaris Observatory, to support informed decision-making at the national, regional, and global level for HCV and HBV elimination. The observatory covers 110 countries for HCV and 135 countries for HBV and provides decision analytics, disease burden modeling, economic impact assessments, and training to help countries with their national hepatitis elimination programs. Results: By providing reliable and up-to-date country specific data and analyses, demonstrating the impact of decisions, and providing costing estimates of national programs, our collaborating countries are making informed decisions. Our economic impact analyses also helped countries fund their elimination programs and negotiate prices. Polaris Observatory is an example of impactful private–public partnership where funding by the John C. Martin Foundation allowed support for informed decision-making by public agencies and national governments who would not/could not support such programs on their own. Conclusions: The catalytic funding allowed the Polaris Observatory to demonstrate the utility of such a program resulting in other donors to support this work. The Polaris Observatory is now supported through a portfolio of funders while our work and outputs remain independent to continue support for viral hepatitis elimination by year 2030.","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44618370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Antiviral prophylaxis for hepatitis B virus in COVID-19 patients treated with immunosuppressive drug therapy 免疫抑制药物治疗新冠肺炎患者乙型肝炎病毒的抗病毒预防
IF 1.2 4区 医学 Q4 INFECTIOUS DISEASES Pub Date : 2022-02-01 DOI: 10.1177/13596535211067602
A. Mastroianni, S. Greco, Luciana Chidichimo, M. Mauro, Filippo Urso, V. Vangeli
To The Editor, We read with great interest the review on COVID-19 and hepatitis B infection by Alqahtani SA and Buti M [1] underlining the need for screening and possible prophylaxis for HBV in patients with COVID-19 receiving corticosteroids and other immunosuppressive agents.The risk of HBV reactivation in patients with HBV surface antigen (HBsAg) /HBV core antibody (HBcAb)+ is estimated to be between 1 and 10% if they are taking moderate-dose (10–20 mg prednisone or equivalent) or high dose (>20 mg prednisone daily or equivalent) of corticosteroids daily for >4 weeks [2]. Hepatitis B virus reactivation can occur in HBsAg-negative patients who have only markers of previous exposure to HBV (HBcAb-positive with or without hepatitis B surface antibody [HBsAb]) [3].To investigate retrospectively the incidence of HBV reactivation in HBsAg /HBcAb+ patients, we reviewed the medical files of 450 patients with Covid-19 admitted at “Annunziata” Hub Hospital, a tertiary care hospital in Cosenza, Italy, between 6 March 2020 and 6 July 2021. Hepatitis B virus virologic indicators were determined at baseline. A total of 60 (34 males and 26 females; median age 69 year, range: 39–87) COVID-19 patients showed evidence of resolved HBV (HBsAg-negative, HBsAb-positive, HBcAb-positive). fifty-five of them patients had at least one comorbidity (most commonly hypertension, diabetes mellitus type 2, and cardiovascular diseases). Forty of the 60 patients met the criteria for severe COVID-19. Five were treated in ICU. Out of these 60 patients, all patients were given corticosteroids, 95 patients received tocilizumab, 40 patients received baricitinib, 30 patients were given anakinra, and 16 patients were treated with canakinumab. Hepatitis B virus virologic indicators were determined at baseline. There were no deaths. They all underwent antiviral prophylaxis with tenofovir disoproxil fumarate, for an average duration of 20 days (14–46 days). They also received antiviral therapy to treat the COVID-19 (remdesivir 50 and lopinavir/ritonavir 10 patients). Ten of those 60 patients had ALTabove normal range (i.e. >45 IU/L). In 12 patients with normal values of ALT at the time of admission there was a rise of ALT above normal range during hospitalization. With recovery from COVID-19, liver function gradually returned to baseline. None of the 60 patients with resolved HBV infection developed clinical evidence of HBV reactivation during 3–6 months of follow-up. We did not observe slower SarsCov2 viral clearance in these patients, while patients with higher HBsAb titers developed higher anti-SarsCov2 antibody titers. There were no adverse events attributable to anti HBV viral prophylaxis. Hepatitis B virus reactivation in subjects undergoing immunosuppressive treatment is recognized as a serious clinical problem. Although the risk of
致编辑:我们非常感兴趣地阅读了Alqahtani SA和Buti M[1]关于COVID-19和乙型肝炎感染的综述,强调需要对接受皮质类固醇和其他免疫抑制剂治疗的COVID-19患者进行筛查和可能的乙型肝炎预防。HBV表面抗原(HBsAg) /HBV核心抗体(HBcAb)+患者如果每天服用中剂量(10 - 20mg强的松或等量)或高剂量(每天20mg强的松或等量)皮质类固醇,持续4周,HBV再激活的风险估计在1 - 10%之间。乙型肝炎病毒再激活可发生在hbsag阴性患者中,这些患者只有既往HBV暴露标志物(hbsag阳性,伴或不伴乙型肝炎表面抗体[HBsAb])[3]。为了回顾性调查HBsAg /HBcAb+患者中HBV再激活的发生率,我们回顾了2020年3月6日至2021年7月6日期间在意大利科森扎的三级保健医院“Annunziata”Hub医院收治的450名Covid-19患者的医疗档案。基线时测定乙型肝炎病毒病毒学指标。共60只(男34只,女26只);中位年龄69岁,范围:39-87)COVID-19患者表现出HBV消退的证据(hbsag阴性、hbsag阳性、hbcab阳性)。其中55例患者至少有一种合并症(最常见的是高血压、2型糖尿病和心血管疾病)。60名患者中有40人符合重症标准。5例在ICU治疗。在这60例患者中,所有患者接受皮质类固醇治疗,95例患者接受tocilizumab治疗,40例患者接受baricitinib治疗,30例患者接受anakinra治疗,16例患者接受canakinumab治疗。基线时测定乙型肝炎病毒病毒学指标。没有人员死亡。所有患者均接受富马酸替诺福韦二氧吡酯抗病毒预防治疗,平均持续时间为20天(14-46天)。他们还接受了抗病毒治疗以治疗COVID-19 (remdesivir 50和洛匹那韦/利托那韦10例)。60例患者中有10例alt高于正常范围(即bb0 - 45 IU/L)。12例入院时ALT值正常的患者在住院期间ALT值高于正常范围。随着COVID-19的恢复,肝功能逐渐恢复到基线。在3-6个月的随访中,60例HBV感染解决的患者中没有出现HBV再激活的临床证据。我们没有观察到这些患者的SarsCov2病毒清除速度较慢,而HBsAb滴度较高的患者的抗SarsCov2抗体滴度较高。没有可归因于抗HBV病毒预防的不良事件。在接受免疫抑制治疗的受试者中,乙型肝炎病毒再激活被认为是一个严重的临床问题。尽管
{"title":"Antiviral prophylaxis for hepatitis B virus in COVID-19 patients treated with immunosuppressive drug therapy","authors":"A. Mastroianni, S. Greco, Luciana Chidichimo, M. Mauro, Filippo Urso, V. Vangeli","doi":"10.1177/13596535211067602","DOIUrl":"https://doi.org/10.1177/13596535211067602","url":null,"abstract":"To The Editor, We read with great interest the review on COVID-19 and hepatitis B infection by Alqahtani SA and Buti M [1] underlining the need for screening and possible prophylaxis for HBV in patients with COVID-19 receiving corticosteroids and other immunosuppressive agents.The risk of HBV reactivation in patients with HBV surface antigen (HBsAg) /HBV core antibody (HBcAb)+ is estimated to be between 1 and 10% if they are taking moderate-dose (10–20 mg prednisone or equivalent) or high dose (>20 mg prednisone daily or equivalent) of corticosteroids daily for >4 weeks [2]. Hepatitis B virus reactivation can occur in HBsAg-negative patients who have only markers of previous exposure to HBV (HBcAb-positive with or without hepatitis B surface antibody [HBsAb]) [3].To investigate retrospectively the incidence of HBV reactivation in HBsAg /HBcAb+ patients, we reviewed the medical files of 450 patients with Covid-19 admitted at “Annunziata” Hub Hospital, a tertiary care hospital in Cosenza, Italy, between 6 March 2020 and 6 July 2021. Hepatitis B virus virologic indicators were determined at baseline. A total of 60 (34 males and 26 females; median age 69 year, range: 39–87) COVID-19 patients showed evidence of resolved HBV (HBsAg-negative, HBsAb-positive, HBcAb-positive). fifty-five of them patients had at least one comorbidity (most commonly hypertension, diabetes mellitus type 2, and cardiovascular diseases). Forty of the 60 patients met the criteria for severe COVID-19. Five were treated in ICU. Out of these 60 patients, all patients were given corticosteroids, 95 patients received tocilizumab, 40 patients received baricitinib, 30 patients were given anakinra, and 16 patients were treated with canakinumab. Hepatitis B virus virologic indicators were determined at baseline. There were no deaths. They all underwent antiviral prophylaxis with tenofovir disoproxil fumarate, for an average duration of 20 days (14–46 days). They also received antiviral therapy to treat the COVID-19 (remdesivir 50 and lopinavir/ritonavir 10 patients). Ten of those 60 patients had ALTabove normal range (i.e. >45 IU/L). In 12 patients with normal values of ALT at the time of admission there was a rise of ALT above normal range during hospitalization. With recovery from COVID-19, liver function gradually returned to baseline. None of the 60 patients with resolved HBV infection developed clinical evidence of HBV reactivation during 3–6 months of follow-up. We did not observe slower SarsCov2 viral clearance in these patients, while patients with higher HBsAb titers developed higher anti-SarsCov2 antibody titers. There were no adverse events attributable to anti HBV viral prophylaxis. Hepatitis B virus reactivation in subjects undergoing immunosuppressive treatment is recognized as a serious clinical problem. Although the risk of","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46818328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adefovir for lamivudine-resistant hepatitis B 阿德福韦治疗拉米夫定耐药乙型肝炎
IF 1.2 4区 医学 Q4 INFECTIOUS DISEASES Pub Date : 2022-02-01 DOI: 10.1177/13596535211067605
Rebecca Roediger, Elizabeth Smyth, D. Dieterich
Adefovir, a nucleotide analog developed by John Martin, was a major breakthrough in the treatment of chronic Hepatitis B. Prior to adefovir, Hepatitis B treatment was limited to two therapeutic modalities, either interferon, which carried significant side effects and was efficacious in a minority of patients, or lamivudine which showed no durable effects with short-term use and a high rate of resistance with long-term use. Adefovir was found to be effective in suppressing viral replication and in resolving the hepatic inflammation associated with hepatitis B with only rare instances of resistance. In this article, we appreciate John Martin’s contribution to science and medicine as we review the landmark trials of adefovir that brought forth a new era of treatment of Hepatitis B.
约翰·马丁开发的核苷酸类似物阿德福韦是治疗慢性乙型肝炎的一个重大突破。在阿德福韦之前,乙型肝炎的治疗仅限于两种治疗方式,一种是干扰素,它具有显著的副作用,对少数患者有效,或拉米夫定,其短期使用无持久效果,长期使用耐药率高。阿德福韦被发现在抑制病毒复制和解决与乙型肝炎相关的肝脏炎症方面有效,只有罕见的耐药性。在这篇文章中,我们感谢约翰·马丁对科学和医学的贡献,因为我们回顾了阿德福韦的里程碑式试验,它开创了乙型肝炎治疗的新时代。
{"title":"Adefovir for lamivudine-resistant hepatitis B","authors":"Rebecca Roediger, Elizabeth Smyth, D. Dieterich","doi":"10.1177/13596535211067605","DOIUrl":"https://doi.org/10.1177/13596535211067605","url":null,"abstract":"Adefovir, a nucleotide analog developed by John Martin, was a major breakthrough in the treatment of chronic Hepatitis B. Prior to adefovir, Hepatitis B treatment was limited to two therapeutic modalities, either interferon, which carried significant side effects and was efficacious in a minority of patients, or lamivudine which showed no durable effects with short-term use and a high rate of resistance with long-term use. Adefovir was found to be effective in suppressing viral replication and in resolving the hepatic inflammation associated with hepatitis B with only rare instances of resistance. In this article, we appreciate John Martin’s contribution to science and medicine as we review the landmark trials of adefovir that brought forth a new era of treatment of Hepatitis B.","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45028259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Antiviral Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1